<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165983</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000233</org_study_id>
    <nct_id>NCT01165983</nct_id>
  </id_info>
  <brief_title>The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes</brief_title>
  <official_title>The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study and determine the effects of Aliskiren on blood
      vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial
      function by 30% or more in comparison to the placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Vasodilation</measure>
    <time_frame>Baseline</time_frame>
    <description>Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Mediated Vasodilation</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
    <description>Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nitroglycerin Induced Dilation</measure>
    <time_frame>Baseline</time_frame>
    <description>Using ultrasound, images are taken pre- and post-vasodilation of the brachial artery induced with a 0.4mg tablet of NTG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nitroglycerine Induced Vasodilation</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
    <description>Using ultrasound, images are taken pre- and post-vasodilation of the brachial artery induced with a 0.4mg tablet of NTG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside</measure>
    <time_frame>Baseline</time_frame>
    <description>Laser doppler imaging is used to measure microcirculatory changes pre- and post-iontophoresis of acetylcholine and sodium nitroprusside.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
    <description>Laser doppler imaging is used to measure microcirculatory changes pre- and post-iontophoresis of acetylcholine (Ach) and sodium nitroprusside (NaNP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Biochemical Markers of Endothelial Function, sICAM-1, ng/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Biochemical Markers of Endothelial Function, sVCAM-1, ng/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Biochemical Markers of Endothelial Function, t-PAI, pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Biochemical Markers of Endothelial Function, C-reactive Protein, μg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Biochemical Markers of Endothelial Function, E-Selectin, ng/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, Osteoprotegerin, pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, Osteopontin, ng/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, G-CSF, pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, GM-CSF pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, IL-8, pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, MCP-1 pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, MDC ng/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, sCD-40L ng/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL</measure>
    <time_frame>12 Weeks post-randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg tablet, taken orally for 12 weeks daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>150mg tablet, taken orally for 12 weeks daily</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Trade name: Tekturna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1. Subjects At Risk of Developing Type 2 Diabetes

        INCLUSION CRITERIA

          1. Ages of 21-80 years

          2. Subjects &quot;at risk&quot; of developing type 2 Diabetes Mellitus (First degree relatives
             history of type 2 Diabetes Mellitus, History of gestational Diabetes, Known impaired
             glucose tolerance, Impaired fasting plasma glucose 100-126 mg/dl at the time of
             enrollment)

        EXCLUSION CRITERIA

          1. Treatment with Aliskiren (Tekturna)

          2. Smokers (use of tobacco products in the previous 3 months)

          3. Active or Uncontrolled Cardiovascular Disease

               -  Myocardial infarction, or angina within 12 months of study participation

               -  Arrhythmia (uncontrolled, highly symptomatic, requiring treatment or
                  life-threatening)

               -  CHF (Class III and IV symptoms of heart failure on less than ordinary exertion or
                  at rest)

               -  Stroke or Transient Ischemic Attack (TIA) within 12 months of study participation

               -  Uncontrolled Hypertension (SBP &gt;180 mmHg or DBP &gt;105 mmHg; 2 abnormal readings
                  during visit)

               -  History of previous hypotensive episodes

          4. Liver Disease (AST, ALT, Alk Phos levels &gt; 2x UNL)

          5. Renal Disease (creatinine &gt; 1.7 mg/dL for women and &gt;2.0 mg/dL for men and/or
             estimated GFR &lt;30 mL/min, history of dialysis, nephrotic syndrome and known
             renovascular hypertension) at the time of enrollment

          6. Hyperkalemia (serum potassium &gt;5.0 meq/L)

          7. Severe Dyslipidemia (TG &gt; 600 mg/dL or Cholesterol &gt;350 mg/dL)

          8. Any Other Serious Chronic Disease Requiring Active Treatment

          9. Females of Childbearing Potential Not Using an Effective Form of Birth Control as
             Determined by co-investigators

         10. Pregnancy

         11. Taking Any of the Following Medications:

               -  Systemic (not inhaled) Glucocorticoids

               -  Antineoplastic Agents

               -  Cyclosporine, Ketoconazole, Furosemide, Warfarin

               -  Bronchodilators (aminophyline, inhaled beta agonists) on a regular basis

         12. Patient is known to have a history of immunodeficiency diseases, including a positive
             HIV (ELISA and Western blot) and/or positive Hepatitis B surface antigen (HBsAg) or
             Hepatitis C test result in the past

         13. History of drug or alcohol abuse within the 12months prior to dosing or evidence of
             such abuse as indicated by laboratory assays conducted during screening or baseline
             evaluations

        Group 2. Type 2 Diabetic Patients

        INCLUSION CRITERIA

          1. Ages of 21-80 years

          2. Type 2 Diabetes Mellitus stable and not expected to change during the study period

        EXCLUSION CRITERIA

          1. Treatment with Aliskiren (Tekturna)

          2. Smokers (use of tobacco products in the previous 3 months)

          3. Active or Uncontrolled Cardiovascular Disease

               -  Myocardial infarction, or angina within 12 months of study participation

               -  Arrhythmia (uncontrolled, highly symptomatic, requiring treatment or
                  life-threatening)

               -  CHF (Class III and IV symptoms of heart failure on less than ordinary exertion or
                  at rest)

               -  Stroke or Transient Ischemic Attack (TIA) within 12 months of study participation

               -  Uncontrolled Hypertension (SBP &gt;180 mmHg or DBP &gt;105 mmHg; 2 abnormal readings
                  during visit)

               -  History of previous hypotensive episodes

          4. Liver Disease (AST, ALT, Alk Phos levels &gt; 2x UNL)

          5. Renal Disease (creatinine &gt; 1.7 mg/dL for women and &gt;2.0 mg/dL for men and/or
             estimated GFR &lt;30 mL/min, history of dialysis, nephrotic syndrome and known
             renovascular hypertension) at the time of enrollment

          6. Hyperkalemia (serum potassium &gt;5.0 meq/L)

          7. Severe Dyslipidemia (TG &gt; 600 mg/dL or Cholesterol &gt;350 mg/dL)

          8. Any Other Serious Chronic Disease Requiring Active Treatment

          9. Females of Childbearing Potential Not Using an Effective Form of Birth Control as
             Determined by co-investigators

         10. Pregnancy

         11. Taking Any of the Following Medications:

               -  Systemic (not inhaled) Glucocorticoids

               -  Antineoplastic Agents

               -  Cyclosporine, Ketoconazole, Furosemide, Warfarin

               -  Bronchodilators (aminophyline, inhaled beta agonists) on a regular basis

         12. Patient is known to have a history of immunodeficiency diseases, including a positive
             HIV (ELISA and Western blot) and/or positive Hepatitis B surface antigen (HBsAg) or
             Hepatitis C test result in the past

         13. History of drug or alcohol abuse within the 12months prior to dosing or evidence of
             such abuse as indicated by laboratory assays conducted during screening or baseline
             evaluations

         14. Severe proliferative retinopathy that renders the subject legally blinded

         15. Previous diagnosis of severe gastroparesis diabeticorum due to autonomic neuropathy
             that has necessitated hospital admission

         16. Presence of non-healing foot ulceration due to severe peripheral diabetic neuropathy

         17. Documented diabetic nephropathy manifested as macro-albuminuria, (2 of 3 urine
             specimens collected within a 3-6 month period with urine albumin&gt;300 ug/mg creatinine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aristidis Veves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Joslin Foot Center &amp; Microcirculation Laboratory</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <results_first_submitted>November 10, 2014</results_first_submitted>
  <results_first_submitted_qc>January 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Aristidis Veves</investigator_full_name>
    <investigator_title>Rongxiang Xu, MD Professor of Surgery in the Field of Regenerative Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 124 subjects signed the ICF, but after screening procedures, 24 were found ineligible so only 100 were randomized to placebo or Aliskiren.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren</title>
          <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren</title>
          <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11"/>
                    <measurement group_id="B2" value="54" spread="11"/>
                    <measurement group_id="B3" value="54" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow Mediated Vasodilation</title>
        <description>Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects at Risk of DMII</title>
          </group>
          <group group_id="O2">
            <title>T2DM Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Vasodilation</title>
          <description>Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.</description>
          <units>percentage change over baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.7"/>
                    <measurement group_id="O2" value="4.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flow Mediated Vasodilation</title>
        <description>Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.</description>
        <time_frame>12 Weeks post-randomization</time_frame>
        <population>Number of subjects that completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Vasodilation</title>
          <description>Using ultrasound, percent change in brachial artery diameter is measured in response to an increase in shear stress from a tightened blood pressure cuff, which causes endothelium-dependent dilatation.</description>
          <population>Number of subjects that completed the study</population>
          <units>percent change over baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.3" upper_limit="1.8"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nitroglycerin Induced Dilation</title>
        <description>Using ultrasound, images are taken pre- and post-vasodilation of the brachial artery induced with a 0.4mg tablet of NTG.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects at Risk of DMII</title>
          </group>
          <group group_id="O2">
            <title>T2DM Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Nitroglycerin Induced Dilation</title>
          <description>Using ultrasound, images are taken pre- and post-vasodilation of the brachial artery induced with a 0.4mg tablet of NTG.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="4.8"/>
                    <measurement group_id="O2" value="15.2" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nitroglycerine Induced Vasodilation</title>
        <description>Using ultrasound, images are taken pre- and post-vasodilation of the brachial artery induced with a 0.4mg tablet of NTG.</description>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Nitroglycerine Induced Vasodilation</title>
          <description>Using ultrasound, images are taken pre- and post-vasodilation of the brachial artery induced with a 0.4mg tablet of NTG.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-2.4" upper_limit="3.7"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-1.8" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-3.9" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-3.4" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside</title>
        <description>Laser doppler imaging is used to measure microcirculatory changes pre- and post-iontophoresis of acetylcholine and sodium nitroprusside.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects at Risk of DMII</title>
          </group>
          <group group_id="O2">
            <title>T2DM Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside</title>
          <description>Laser doppler imaging is used to measure microcirculatory changes pre- and post-iontophoresis of acetylcholine and sodium nitroprusside.</description>
          <units>percentage change over baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acetylcholine induced skin vasodilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="19" upper_limit="62"/>
                    <measurement group_id="O2" value="38" lower_limit="22" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium nitroprusside skin induced vasodilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="23" upper_limit="61"/>
                    <measurement group_id="O2" value="36" lower_limit="20" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside</title>
        <description>Laser doppler imaging is used to measure microcirculatory changes pre- and post-iontophoresis of acetylcholine (Ach) and sodium nitroprusside (NaNP).</description>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside</title>
          <description>Laser doppler imaging is used to measure microcirculatory changes pre- and post-iontophoresis of acetylcholine (Ach) and sodium nitroprusside (NaNP).</description>
          <units>percent change over baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Ach, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="-31" upper_limit="37"/>
                    <measurement group_id="O2" value="-1" lower_limit="-43" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At risk of T2DM, NaNP, Placebo n=21 Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-23" upper_limit="30"/>
                    <measurement group_id="O2" value="13" lower_limit="-34" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patient, Ach, Placebo n=25 Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-34" upper_limit="11"/>
                    <measurement group_id="O2" value="3" lower_limit="-48" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patient, NaNP, Placebo n=25 Ali. n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-21" upper_limit="5"/>
                    <measurement group_id="O2" value="8" lower_limit="-5" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Biochemical Markers of Endothelial Function, sICAM-1, ng/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Biochemical Markers of Endothelial Function, sICAM-1, ng/mL</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="-8" upper_limit="59"/>
                    <measurement group_id="O2" value="30" lower_limit="-7" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="-25" upper_limit="45"/>
                    <measurement group_id="O2" value="14" lower_limit="-13" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Biochemical Markers of Endothelial Function, sVCAM-1, ng/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Biochemical Markers of Endothelial Function, sVCAM-1, ng/mL</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335" lower_limit="-263" upper_limit="629"/>
                    <measurement group_id="O2" value="236" lower_limit="-216" upper_limit="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" lower_limit="-91" upper_limit="651"/>
                    <measurement group_id="O2" value="106" lower_limit="-124" upper_limit="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Biochemical Markers of Endothelial Function, t-PAI, pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Biochemical Markers of Endothelial Function, t-PAI, pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="-29" upper_limit="66"/>
                    <measurement group_id="O2" value="30" lower_limit="-15" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="-59" upper_limit="93"/>
                    <measurement group_id="O2" value="26" lower_limit="-42" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Biochemical Markers of Endothelial Function, C-reactive Protein, μg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Biochemical Markers of Endothelial Function, C-reactive Protein, μg/mL</title>
          <units>μg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-2.6" upper_limit="10.9"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-15.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-17.5" upper_limit="5.5"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-6.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Biochemical Markers of Endothelial Function, E-Selectin, ng/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Biochemical Markers of Endothelial Function, E-Selectin, ng/mL</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-1.7" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-2.1" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-18.5" upper_limit="4.9"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-48.1" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, Osteoprotegerin, pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, Osteoprotegerin, pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36" lower_limit="-78" upper_limit="80"/>
                    <measurement group_id="O2" value="97" lower_limit="15" upper_limit="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24" lower_limit="-86" upper_limit="75"/>
                    <measurement group_id="O2" value="48" lower_limit="-24" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, Osteopontin, ng/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, Osteopontin, ng/mL</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-5.9" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-0.8" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="-1.3" upper_limit="7.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-6.1" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, G-CSF, pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, G-CSF, pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-8.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-0.8" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-11.4" upper_limit="10.6"/>
                    <measurement group_id="O2" value="4.4" lower_limit="-7.8" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, GM-CSF pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, GM-CSF pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-1.3" upper_limit="3.7"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-1.4" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-6.3" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.2" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, IL-8, pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, IL-8, pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-5.8" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-5.0" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-5.9" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-2.6" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, MCP-1 pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, MCP-1 pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-125" upper_limit="23"/>
                    <measurement group_id="O2" value="-7" lower_limit="-112" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="-76" upper_limit="110"/>
                    <measurement group_id="O2" value="8" lower_limit="-154" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, MDC ng/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, MDC ng/mL</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" lower_limit="-0.32" upper_limit="0.11"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.32" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.46" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.36" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, sCD-40L ng/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, sCD-40L ng/mL</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-3.8" upper_limit="2.7"/>
                    <measurement group_id="O2" value="-3.2" lower_limit="-9.6" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="-1.5" upper_limit="12.8"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-7.9" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL</title>
        <time_frame>12 Weeks post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Inflammatory Cytokines and Growth Factors, TNFα, pg/mL</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At risk of T2DM, Placebo n=21, Aliskiren n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" lower_limit="-0.78" upper_limit="1.80"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-1.65" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic Patients, Placebo n=25, Aliskiren n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="-3.26" upper_limit="1.67"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-3.20" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number for &quot;at risk&quot; of Diabetic Ketoacidosis reduced to reflect number of subjects enrolled who were diagnosed with T2DM. Diabetic ketoacidosis is primarily a concern in patients with T1DM, however the patient who experienced ketoacidosis was later shown to have undiagnosed T1DM, improperly diagnosed as T2DM.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: 0mg tablet, taken orally for 12 weeks daily</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren</title>
          <description>Aliskiren: 150mg tablet, taken orally for 12 weeks daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Increase in eosinophil levels</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in Blood Glucose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GI virus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Bloating and gas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mild increase in Serum Calcium Level</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Increase in serum creatinine levels</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Decrease in serum calcium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness and cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aristidis Veves, Research Director</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-632-7075</phone>
      <email>aveves@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

